Skip to main content
CELL BIOTECH CO ., LTD logo

CELL BIOTECH CO ., LTD — Investor Relations & Filings

Ticker · 049960 ISIN · KR7049960008 KO Manufacturing
Open in API
Filings indexed 189 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 049960

About CELL BIOTECH CO ., LTD

https://www.cellbiotech.com/

CELL BIOTECH CO., LTD. is a biotechnology company specializing in the research, development, and manufacturing of probiotic solutions. With over three decades of experience, the company leverages its proprietary, worldwide-patented dual-coating technology, which is designed to ensure a higher survival rate for probiotic strains as they pass through the gastrointestinal tract. The company develops and utilizes its own GRAS (Generally Recognized as Safe) certified strains for its products. Its business encompasses the production of finished consumer products, such as the DUOLAC brand, and providing customized OEM/ODM services for the pharmaceutical and food supplement sectors.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is labeled “분기보고서” (Quarterly Report) covering the period 2026-01-01 to 2026-03-31 (제32기 1분기). It includes detailed business overview, product and sales data, R&D activities, and extensive quantitative tables – all characteristic of an interim/quarterly financial filing rather than a simple earnings release or announcement. It is not merely a short notice or certification but the full quarterly report itself. Therefore, it should be classified as an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled as a preliminary (잠정) consolidated financial performance announcement for the period 2026-01-01 to 2026-03-31, which corresponds to a quarterly period. It contains summarized financial data such as sales, operating profit, and net income for the current quarter and comparisons to previous periods. The document explicitly states that the figures are provisional and subject to change after audit review. The length is about 2396 characters, which is relatively short and typical for an earnings release or preliminary financial results announcement. There is no indication that this is a full interim report with detailed financial statements or management discussion, but rather a summary of key financial results. Therefore, the document fits best as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Q1 2026
2026-05-08 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 72% confidence The document is a voluntary corporate disclosure (‘자율공시’) outlining a future corporate value enhancement plan focused on dividend policy and shareholder return measures, without announcing a specific upcoming dividend amount or payment date. It does not fit into Dividend Notice (DIV), Capital Financing (CAP), or regular financial reports (10-K, IR, ER). As a miscellaneous regulatory announcement that doesn’t match any of the more specific categories, it falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official results of the Regular Shareholders’ Meeting (Annual General Meeting) held on 2026-03-26, detailing vote outcomes for each resolution, dividend approvals, financial statement approvals, and director appointments. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 97% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) filed by Cell Biotech. It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, operating profit), and details regarding the external auditor (Samil PwC). While it contains financial data, it is a regulatory disclosure announcement regarding the submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it fits the criteria for a regulatory filing announcement. FY 2025
2026-03-18 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Cell Biotech (주식회사 쎌바이오텍) for the fiscal year ending December 31, 2025. It includes the independent auditor's report from Samil PricewaterhouseCoopers, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. This is a comprehensive annual financial disclosure, which falls under the 'Audit Report' category as it contains the audit opinion and the full set of audited financial statements. FY 2025
2026-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.